Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Relypsa: FDA Issuance of a CRL for ZS-9 is a Significant Positive (RLYP, Buy, $18.50)

Investment Thesis The receipt of a CRL for ZS-9 delays its possible approval by perhaps one year or more which substantially enhances the first mover advantage of Veltassa. AZN comments on the CRL minimize the potential that the mechanism of action of ZS-9 (which exchanges sodium for potassium) is a safety concern, but I am […]

«Older Posts
«Older Posts
Search Graphic